In:
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, Wiley, Vol. 11, No. 1 ( 2019-12), p. 483-492
Abstract:
Plasma tau may be an accessible biomarker for Alzheimer's disease (AD), but the correlation between plasma and cerebrospinal fluid (CSF) tau and the value of combining plasma tau with CSF tau and phospho‐tau (P‐tau) are still unclear. Methods Plasma‐tau, CSF‐tau, and P‐tau were measured in 97 subjects, including elderly cognitively normal controls (n = 68) and patients with AD (n = 29) recruited at the NYU Center for Brain Health, with comprehensive neuropsychological and magnetic resonance imaging evaluations. Results Plasma tau was higher in patients with AD than cognitively normal controls ( P 〈 .001, area under the receiver operating characteristic curve = 0.79) similarly to CSF tau and CSF P‐tau and was negatively correlated with cognition in AD. Plasma and CSF tau measures were poorly correlated. Adding plasma tau to CSF tau or CSF P‐tau significantly increased the areas under the receiver operating characteristic curve from 0.80 and 0.82 to 0.87 and 0.88, respectively. Discussion Plasma tau is higher in AD independently from CSF‐tau. Importantly, adding plasma tau to CSF tau or P‐tau improves diagnostic accuracy, suggesting that plasma tau may represent a useful biomarker for AD, especially when added to CSF tau measures.
Type of Medium:
Online Resource
ISSN:
2352-8729
,
2352-8729
DOI:
10.1016/j.dadm.2019.05.001
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
2832898-X
